Clinical trials: Adult ALL
Hearing Loss
Cochlear Implantation in Adults With Asymmetric Hearing Loss Clinical Trial
This longitudinal study evaluates the possible benefit of cochlear implantation in the poor ear of adults with asymmetric hearing loss who continue to use a hearing aid in the better hearing ear.
- Trial name
- NCT03052920
- Testing
- Cochlear implant
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Healthy
Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults
To assess the relative bioavailability of ALXN1840 administered orally as a single enteric-coated (EC) tablet (reference, Treatment A) versus three EC tablets (test, Treatment B).
- Trial name
- NCT05303324
- Testing
- ALXN1840
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.
Influenza, Human
A Study to Assess the Immunogenicity and Safety of CSL's 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers
This is a study to assess the immune (antibody) response and safety of the 2013/2014 formulation of Enzira® vaccine in healthy adult volunteers aged 18 years or older.
- Trial name
- NCT01857297
- Testing
- Enzira® vaccine
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Seqirus
Glabellar Lines
A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT05248880
- Testing
- AGN-151586
- Where
- 17 sites in United States, Canada
- Volunteers
- 309 people
- Sponsor
- AbbVie
Solid Tumor, Solid Carcinoma
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
The purpose of this study is to find out whether the study drug benralizumab is a safe treatment that can reduce the skin side effects caused by cancer treatment by reducing the level of eosinophils in your blood.
- Conditions
- Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Hematologic Malignancy
- Trial name
- NCT04552288
- Testing
- Benralizumab
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Carcinoma, Non-Small-Cell Lung
Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer
The purpose of this trial was to evaluate the safety and efficacy of capmatinib in combination with spartalizumab in adult participants with epidermal growth factor receptor (EGFR) wild type (for exon 19 deletions and exon 21…
- Trial name
- NCT03647488
- Testing
- Capmatinib, Spartalizumab, Docetaxel
- Where
- 8 sites in United States, Belgium and 4 more
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
Herpes Zoster
A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009)
This is a study to evaluate the safety and immunogenicity of V212 vaccine in adults with autoimmune disease, including participants with rheumatoid arthritis, psoriatic arthritis, psoriasis, inflammatory bowel disease, systemic…
- Trial name
- NCT01527383
- Testing
- V212
- Volunteers
- 354 people
- Sponsor
- Merck Sharp & Dohme LLC
Oral Mucositis
Study to Characterize the Effect of Heparin on Palifermin Activity
The purpose of this study is to evaluate the effect of a continuous intravenous infusion of unfractionated heparin on the multiple-dose pharmacodynamics of palifermin in healthy adult subjects.
- Trial name
- NCT01163097
- Testing
- Palifermin, Heparin
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Swedish Orphan Biovitrum
Thrombosis
Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects
The purpose of this study is to assess the safety, tolerability and pharmacodynamics of a single iv dose of E-WE Thrombin in healthy adult subjects.
- Trial name
- NCT03453060
- Testing
- E-WE Thrombin- Dose 1, E-WE Thrombin- Dose 2, E-WE Thrombin- Dose 3
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Aronora, Inc.
Type 1 Diabetes Mellitus
Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System
This study is a Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects.
- Trial name
- NCT03959423
- Testing
- AHCL insulin pump system
- Where
- 17 sites in United States
- Volunteers
- 288 people
- Sponsor
- Medtronic MiniMed, Inc.
Migraine, With or Without Aura
Safety and Efficacy Study in Adult Subjects With Acute Migraines
The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant) versus placebo in subjects with Acute Migraines
- Trial name
- NCT03235479
- Testing
- Rimegepant
- Where
- 50 sites in United States
- Volunteers
- 1,485 people
- Sponsor
- Pfizer
Healthy Volunteers
A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by Syringe Injection Versus Pen Injector in Healthy Adult Participants
The purpose of this study is to evaluate the bioavailability of teduglutide administered as a single subcutaneous (SC) fixed dose (depending upon participant weightband assignment) delivered by a syringe injection and the same…
- Trial name
- NCT04465396
- Testing
- Teduglutide, Syringe Injection, Pen injector
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Shire
X-linked Hypophosphatemia
An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
The primary purpose of this study is to assess the safety and efficacy of repeated subcutaneous (SC) injections of KRN23 in adult subjects with X-Linked Hypophosphatemia (XLH).
- Trial name
- NCT01571596
- Testing
- KRN23
- Where
- 6 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Chronic Spontaneous Urticaria
A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines
The purpose of this study was to establish safety and efficacy of ligelizumab in adolescent and adult subjects with Chronic Spontaneous Urticaria (CSU) who remain symptomatic despite standard of care treatment by demonstrating…
- Trial name
- NCT03580369
- Testing
- Ligelizumab, Omalizumab
- Where
- 161 sites in United States, Argentina and 27 more
- Volunteers
- 1,072 people
- Sponsor
- Novartis Pharmaceuticals
COVID-19
VA CoronavirUs Research and Efficacy Studies-1
The purpose of this study is to determine if treatment with convalescent plasma improves the clinical outcomes of Veterans who are hospitalized and require supplemental oxygen due to COVID-19.
- Trial name
- VACURES-1 (NCT04539275)
- Testing
- Convalescent Plasma
- Where
- 24 sites in United States, Puerto Rico
- Volunteers
- 75 people
- Sponsor
- VA Office of Research and Development
Muscular Dystrophies
First Time in Human (FTIH) Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of GSK3439171A in Healthy Subjects and to Assess Food Effect
The FTIH study with GSK3439171A will evaluate the safety of GSK3439171A in healthy subjects in order to avoid confounding factors due to the disease or concomitant drugs in patients.
- Trial name
- NCT03627494
- Testing
- GSK3439171A
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acute Myeloid Leukemia
A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy
This trial seeked to extend the preliminary findings of efficacy by evaluating MBG453 in combination with hypomethylating agents (HMA) and also Bcl-2 inhibitor venetoclax.
- Trial name
- STIMULUS-AML1 (NCT04150029)
- Testing
- MBG453, Venetoclax, Azacitidine
- Where
- 28 sites in United States, Australia and 8 more
- Volunteers
- 90 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer
Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)
The purpose of this study is to evaluate the efficacy and safety of pemetrexed plus platinum chemotherapy (carboplatin or cisplatin) with or without pembrolizumab (MK-3475; KEYTRUDA®) in the treatment of adults with the following…
- Trial name
- NCT03515837
- Testing
- pembrolizumab, pemetrexed, carboplatin
- Where
- 158 sites in United States, Australia and 15 more
- Volunteers
- 492 people
- Sponsor
- Merck Sharp & Dohme LLC
Adult Glioblastoma, Adult Gliosarcoma
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
This randomized phase II trial is studying the side effects and how well giving bevacizumab together with irinotecan or temozolomide works in treating patients with recurrent or refractory glioblastoma multiforme or gliosarcoma.
- Conditions
- Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
- Trial name
- NCT00433381
- Testing
- Bevacizumab, Irinotecan Hydrochloride, Temozolomide
- Where
- 93 sites in United States
- Volunteers
- 123 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
This pilot clinical trial studies the side effects of cytarabine and daunorubicin hydrochloride and to see how well they work in treating patients with newly diagnosed acute myeloid leukemia.
- Trial name
- NCT02971397
- Testing
- Bone Marrow Aspiration and Biopsy, Cytarabine, Daunorubicin Hydrochloride
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wake Forest University Health Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.